Calliditas Therapeutics AB Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-12-17: Study NCT06712407; Company role Lead sponsor; Phase Phase 4; Status Active not recruiting.
- 2023-11-27: Study NCT06274489; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Completed.
- 2020-11-17: Study NCT04541043; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2020-06-24: Study NCT04327089; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-12-17 | NCT06712407 Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | Lead sponsor | Phase 4 | Active not recruiting | IgA Nephropathy | 60 | 2028-02 |
| 2023-11-27 | NCT06274489 A Study to Evaluate Setanaxib in Patients With Alport Syndrome | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Alport Syndrome | 20 | 2025-06-25 |
| 2020-11-17 | NCT04541043 Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) | Lead sponsor | Phase 3 | Completed Results posted | Primary IgA Nephropathy | 119 | 2024-02-26 |
| 2020-06-24 | NCT04327089 Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects | Lead sponsor | Phase 1 | Completed | Phase 1 | 64 | 2021-03-23 |
| 2018-12-19 | NCT03740217 Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets | Lead sponsor | Phase 1 | Completed | Phase 1 | 15 | 2019-02-06 |
| 2018-09-05 | NCT03643965 Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy | Lead sponsor | Phase 3 | Completed Results posted | Primary IgA Nephropathy | 365 | 2023-07-10 |
| 2017-06-26 | NCT03226067 Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. | Lead sponsor | Phase 2 | Completed Results posted | Primary Biliary Cirrhosis | 111 | 2019-04-11 |
| 2013-10 | NCT02010242 Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria | Lead sponsor | Phase 2 | Completed Results posted | Type 2 Diabetes Mellitus With Diabetic Nephropathy | 136 | 2015-03 |
| 2012-12 | NCT01738035 The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease | Lead sponsor | Phase 2 | Completed | Primary IgA Nephropathy | 150 | 2015-09 |
| 2005-10 | NCT00767221 Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study | Lead sponsor | Phase 2 | Completed | IGA Nephropathy | 20 | 2008-11 |
| 2001-01 | NCT00160082 Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS) | Lead sponsor | Not applicable | Completed | Post Polio Syndrome, PPS | 124 | 2003-05 |